Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593121552> ?p ?o ?g. }
- W2593121552 endingPage "3" @default.
- W2593121552 startingPage "3" @default.
- W2593121552 abstract "Abstract Background: Earlier data demonstrated long-term expression of factor IX (mean FIX:C ~5.1%) following AAV8-mediated gene transfer at 2 x1012 vg/kg in hemophilia B (Nathwani et al., 2014). While the clinical improvement imparted by stable FIX levels is clear, these levels of expression fall short of trough values obtained by long-acting FIX prophylaxis (Santagostino et al. 2016), and of natural history data suggesting that levels of ~12% are required to eliminate spontaneous hemarthroses (den Uijl et al. 2011). Achieving higher levels of FIX:C with dose escalation has not been possible without eliciting a dose-dependent, capsid-specific immune response that may prevent sustained expression and efficacy (Mingozzi et al. 2007, Monahan et al. 2015). We sought to develop a highly efficient vector capsid and expression cassette that could be administered at low doses to achieve hemostatic FIX expression without need for immunosuppression. Methods: The investigational product, SPK-9001, utilizes a bioengineered AAV capsid (Spark100) with liver specific tropism. The prevalence of neutralizing antibodies (NAb) to Spark100 among sampled hemophilia B sera was 40% (Anguela et al. 2015). The expression cassette is a codon-optimized, single-stranded transgene encoding FIX Padua, a naturally occurring variant with a single amino acid substitution (R338L) that confers ~8-fold greater specific activity compared to wild-type FIX (Simioni et al. 2009). Data on bleeding and factor infusions in the year prior to enrollment were retrospectively compiled. Laboratory values, bleeding frequency, FIX consumption, changes in activity and quality-of-life via Haem-A-QoL were prospectively evaluated after vector infusion. Results: We enrolled 9 subjects, of whom 2 failed screening for liver fibrosis and 7 were infused with SPK-9001 at a dose of 5 x1011 vg/kg. Infused subjects were adult males ages 18-52 years with baseline FIX:C </=2% and Spark100 NAb titer of <1:1 or 1:1. Table 1 outlines infused subject data with a follow up interval of >2-34 weeks after vector infusion. Figure 1 outlines subject vector-derived FIX:C for the first 12 weeks. There have been no vector or procedure related adverse events. Steady-state FIX expression is reached by 12 weeks after vector infusion, resulting in a mean FIX:C of 32.3% ±6.5%. To date, no subjects required immunosuppression or demonstrated evidence of a cytotoxic immune response (characterized by loss of FIX activity, elevation of transaminase values >/=1.5-times the upper limit of normal, and positive IFN-gammaELISPOT response to capsid peptides). No subjects developed a FIX inhibitor or demonstrated ELISPOT reactivity to the FIX (R338L) gene product. Subject 3 infused with FIX concentrate for a suspected ankle bleed 2 days after vector infusion. Beyond this, no subjects required factor or experienced any bleeding events. The 4 subjects previously maintained on prophylaxis safely stopped without break-through bleeding. As of today (cumulative 724 days post vector infusion), total factor consumption was reduced by 543,589 IU, tantamount to a cumulative savings of $1,182,298 USD.Six of 7 subjects report increased physical activity and improved quality of life. Conclusion: As of 8/4/2016, we report the highest and most consistent levels of sustained vector-derived FIX:C following FIX gene transfer. Levels of FIX:C achieved by SPK-9001 permitted termination of prophylaxis, prevention of bleeding, and nearly complete cessation of factor use. Despite the heterogeneity in subjects with respect to presence and extent of hemophilic arthropathy, age, and co-morbidities, consistency of transgene expression and clinical outcomes have been observed in all participants studied to date. A vector dose of 5x1011 vg/kg is the lowest dose currently reported in hemophilia gene transfer trials; the absence of any observed CD8+ T cell immune response supports the hypothesis that lowering the dose can reduce or eliminate the risk of a capsid-specific immune response and maximize efficacy. In summary, preliminary data suggest SPK-9001 safely and consistently produces sustained elevation in FIX:C levels sufficient to prevent spontaneous hemarthroses without the need for factor consumption or immunosuppression. Disclosures Ducore: Octapharama: Membership on an entity's Board of Directors or advisory committees; LFB: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Biogen: Membership on an entity's Board of Directors or advisory committees; CSL Behring: Membership on an entity's Board of Directors or advisory committees; Baxalta (Shire): Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees. Cuker:Biogen-Idec: Consultancy, Research Funding; T2 Biosystems: Research Funding; Genzyme: Consultancy; Stago: Consultancy; Amgen: Consultancy. McGuinn:Spark: Research Funding; Biogen: Research Funding; Novo Nordisk: Research Funding; Baxalta: Research Funding. Luk:Spark Therapeutics, Inc.: Employment. Wright:Spark Therapeutics, Inc.: Employment, Equity Ownership, Patents & Royalties: SPK-9001. Chen:Spark Therapeutics, Inc.: Employment. Hui:Spark Therapeutics, Inc.: Employment. Wachtel:Spark Therapeutics, Inc.: Employment. Urich:Spark Therapeutics, Inc.: Employment. Takefman:Spark Therapeutics, Inc.: Employment. Couto:Spark Therapeutics, Inc.: Employment. Carr:Pfizer, Inc.: Research Funding. Anguela:Spark Therapeutics, Inc.: Employment, Patents & Royalties: SPK-9001. High:Spark Therapeutics, Inc.: Employment, Equity Ownership, Patents & Royalties: SPK-9001." @default.
- W2593121552 created "2017-03-16" @default.
- W2593121552 creator A5004249526 @default.
- W2593121552 creator A5006247864 @default.
- W2593121552 creator A5008052776 @default.
- W2593121552 creator A5010600720 @default.
- W2593121552 creator A5020371767 @default.
- W2593121552 creator A5026159764 @default.
- W2593121552 creator A5033277247 @default.
- W2593121552 creator A5047366587 @default.
- W2593121552 creator A5049404381 @default.
- W2593121552 creator A5051144478 @default.
- W2593121552 creator A5051578642 @default.
- W2593121552 creator A5060779925 @default.
- W2593121552 creator A5064441554 @default.
- W2593121552 creator A5070077240 @default.
- W2593121552 creator A5070714730 @default.
- W2593121552 creator A5071048526 @default.
- W2593121552 creator A5073892799 @default.
- W2593121552 creator A5075244777 @default.
- W2593121552 creator A5083665350 @default.
- W2593121552 creator A5084231462 @default.
- W2593121552 creator A5085444099 @default.
- W2593121552 date "2016-12-02" @default.
- W2593121552 modified "2023-10-06" @default.
- W2593121552 title "Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression" @default.
- W2593121552 doi "https://doi.org/10.1182/blood.v128.22.3.3" @default.
- W2593121552 hasPublicationYear "2016" @default.
- W2593121552 type Work @default.
- W2593121552 sameAs 2593121552 @default.
- W2593121552 citedByCount "15" @default.
- W2593121552 countsByYear W25931215522017 @default.
- W2593121552 countsByYear W25931215522018 @default.
- W2593121552 countsByYear W25931215522020 @default.
- W2593121552 crossrefType "journal-article" @default.
- W2593121552 hasAuthorship W2593121552A5004249526 @default.
- W2593121552 hasAuthorship W2593121552A5006247864 @default.
- W2593121552 hasAuthorship W2593121552A5008052776 @default.
- W2593121552 hasAuthorship W2593121552A5010600720 @default.
- W2593121552 hasAuthorship W2593121552A5020371767 @default.
- W2593121552 hasAuthorship W2593121552A5026159764 @default.
- W2593121552 hasAuthorship W2593121552A5033277247 @default.
- W2593121552 hasAuthorship W2593121552A5047366587 @default.
- W2593121552 hasAuthorship W2593121552A5049404381 @default.
- W2593121552 hasAuthorship W2593121552A5051144478 @default.
- W2593121552 hasAuthorship W2593121552A5051578642 @default.
- W2593121552 hasAuthorship W2593121552A5060779925 @default.
- W2593121552 hasAuthorship W2593121552A5064441554 @default.
- W2593121552 hasAuthorship W2593121552A5070077240 @default.
- W2593121552 hasAuthorship W2593121552A5070714730 @default.
- W2593121552 hasAuthorship W2593121552A5071048526 @default.
- W2593121552 hasAuthorship W2593121552A5073892799 @default.
- W2593121552 hasAuthorship W2593121552A5075244777 @default.
- W2593121552 hasAuthorship W2593121552A5083665350 @default.
- W2593121552 hasAuthorship W2593121552A5084231462 @default.
- W2593121552 hasAuthorship W2593121552A5085444099 @default.
- W2593121552 hasConcept C104317684 @default.
- W2593121552 hasConcept C111599444 @default.
- W2593121552 hasConcept C126322002 @default.
- W2593121552 hasConcept C159047783 @default.
- W2593121552 hasConcept C159654299 @default.
- W2593121552 hasConcept C202878990 @default.
- W2593121552 hasConcept C203014093 @default.
- W2593121552 hasConcept C2522874641 @default.
- W2593121552 hasConcept C2780073493 @default.
- W2593121552 hasConcept C2780252810 @default.
- W2593121552 hasConcept C2781221834 @default.
- W2593121552 hasConcept C54355233 @default.
- W2593121552 hasConcept C71924100 @default.
- W2593121552 hasConcept C86803240 @default.
- W2593121552 hasConceptScore W2593121552C104317684 @default.
- W2593121552 hasConceptScore W2593121552C111599444 @default.
- W2593121552 hasConceptScore W2593121552C126322002 @default.
- W2593121552 hasConceptScore W2593121552C159047783 @default.
- W2593121552 hasConceptScore W2593121552C159654299 @default.
- W2593121552 hasConceptScore W2593121552C202878990 @default.
- W2593121552 hasConceptScore W2593121552C203014093 @default.
- W2593121552 hasConceptScore W2593121552C2522874641 @default.
- W2593121552 hasConceptScore W2593121552C2780073493 @default.
- W2593121552 hasConceptScore W2593121552C2780252810 @default.
- W2593121552 hasConceptScore W2593121552C2781221834 @default.
- W2593121552 hasConceptScore W2593121552C54355233 @default.
- W2593121552 hasConceptScore W2593121552C71924100 @default.
- W2593121552 hasConceptScore W2593121552C86803240 @default.
- W2593121552 hasIssue "22" @default.
- W2593121552 hasLocation W25931215521 @default.
- W2593121552 hasOpenAccess W2593121552 @default.
- W2593121552 hasPrimaryLocation W25931215521 @default.
- W2593121552 hasRelatedWork W1528827813 @default.
- W2593121552 hasRelatedWork W1969271865 @default.
- W2593121552 hasRelatedWork W1969386671 @default.
- W2593121552 hasRelatedWork W1998962854 @default.
- W2593121552 hasRelatedWork W2006514888 @default.
- W2593121552 hasRelatedWork W2039540399 @default.
- W2593121552 hasRelatedWork W2098516138 @default.
- W2593121552 hasRelatedWork W2127511777 @default.
- W2593121552 hasRelatedWork W2139983200 @default.
- W2593121552 hasRelatedWork W2188478563 @default.